India: IPO Rejects Compulsory Licensing Application Against The Patented Drug SAXAGLIPTIN By Lee Pharma


An application for Compulsory Licensing against 'SAXAGLIPTIN' drug was filed by Lee Pharma, a Hyderabad based Indian pharma company, dated 29.06.2015.'SAXAGLIPTIN' is protected by the patent IN 206543 entitled "A Cyclopropyl-fused pyrrolidinebased compound" granted to Bristol Myers Squibb (BMS) which was subsequently assigned to AstraZeneca by way of deed of assignment. An order issued by IPO on 12th August, 2015, rejecting the application under Rule 97(1) of the Patent Rules, 2003. The Applicant requested a further hearing which was granted on 15/12/2015 along with supplementary submissions on 29/12/2015. Subsequent to this hearing, the IPO passed an order1 dated 19/01/2016 in which the Controller rejected the application for largely the same reasons as stated in its earlier order.

Facts of the case:

SAXAGLIPTIN is a Dipeptidyl Peptidase-4 (DPP-4) inhibitor used in the treatment of Type II Diabetes Mellitus. The drug SAXAGLIPTIN is sold under the brand name 'ONGLYZA' in dosages of 2.5 mg and 5 mg. SAXAGLIPTIN in combination with Metformin is sold under the brand name 'KOMBIGLYZE XR' in dosage 5/500 mg and 5/1000 mg.

Grounds relied by the Applicant for making an application for Compulsory Licensing:

Section 84(1) (a): That the reasonable requirements of the public with respect to the patented invention have not been satisfied

The Applicant submitted that there are nearly 60 million people in India suffering from Type II DM and even if 1 million people were prescribed SAXAGLIPTIN then total number of tablets required for one million patients in one year would be 365,000,000 tablets per year. From Form-27 data submitted by the patentee , the Applicant mentioned the total number of ONGLYZA and KOMBIGLYZE imported for the whole year was

0.23% of the total number required for a year. Hence the Applicant submitted that there is more than 99% of shortage of SAXAGLIPTIN in the Indian market. Upon hearing the arguments of the Applicant, the Learned Controller insisted on authentic report for the data provided on increased diabetic population as well as the number of Type-II DM patients taking prescribed medicines in relation to other steps such as lifestyle change, dietary changes, exercise etc, but the Applicant could not provide authentic data.

Further, the Applicant did not provide any comparative data of SAXAGLIPTIN and other DPP-4 inhibitors such as Linagliptin, Sitagliptin and Vildagliptin which are also available in Indian market so that the reasonable requirements of the public in respect to SAXAGLIPTIN could be arrived. The learned Controller quoted the matter of 'Bayer Corporation Vs Union of India & Ors' which held that in respect of medicines the adequate test has to be 100% i.e to the fullest extent.

Hence the Controller stated that it was unclear from the Applicant's submission whether one million patients need SAXAGLIPTIN despite other alternatives such as Linagliptin, Sitagliptin and Vildagliptin. In the absence of authentic data, there is no way to understand the exact requirements of SAXAGLIPTIN in Indian market to decide or not whether the patentee is meeting with the reasonable requirements of the public in respect to patented invention.

With regards to the above mentioned details, the Controller stated that a prima facie case has not been made out by the Applicant to the effect that the reasonable requirements of the public with respect to the patented invention are not being satisfied and therefore, no case is made out in terms of Clause (a) of section 84 of the Indian Patents Act.

Section 84(1)(b) – That the patented invention is not available to the public at a reasonably affordable price

The Applicant submitted that excessive high price of SAXAGLIPTIN is a barrier for the poor patients in India hence, it is unavailable to a general public at a reasonably affordable price. The Controller again quoted Bayer v. Union of India to hold that the Controller does not have any power of investigations to arrive at a reasonably affordable price, and that such a price must be arrived at on the basis of evidence led by the parties.

The Controller observed that the prices of other DPP-4 inhibitors available in the Indian market despite such large volumes and side effects are also in the same range (Rs.42 to 58) which are at par with the patentee's SAXAGLIPTIN (i.e Rs.41 to 49) based on the daily requirements. Based on the figures submitted by the patentee in Form-27 on 10/02/2014 the Applicant calculated the cost of importing one tablet of ONGLYZA and KOMBIGLYZE in India by the Patentee is only about Rs.0.80 and Rs.0.92 respectively. But the Applicant priced two medicines ONGLYZA and KOMBIGLYZE in the range of Rs.41 to 49 per tablet. Therefore, the Applicant alleged that the patentee remain a monopoly due to high pricing of the drugs despite the small amount of cost involved in manufacturing/importing a single tablet.

However, ironically the Applicant in its application for Compulsory Licensing initially proposed it selling price as Rs.27 to 32 per tablet but eventually revised its price during hearing held on 15/12/2015 in the range of Rs.11 to 16.

It was highlighted by the Controller that the Applicant in its submissions has not furnished the details of reasonable requirements of the public with respect to SAXAGLIPTIN, the comparative requirements of SAXAGLIPTIN and other DPP-4 inhibitors Lindagliptin, Sitagliptin and Vildagliptin or any authentic data or statistics on SAXAGLIPTIN prescription by the doctors over the other DPP-4 inhibitors. Hence in the absence of all the critical data above, the question of SAXAGLIPTIN'S availability and affordability can't be determined. Therefore the Applicant failed to prima facie show that the patented invention is not available to the public at a reasonably affordable price.

Section 84 (1) (c): That the patented invention is not worked in the territory of India

The Controller in this regard reasoned his findings from the judgment of Honorable Bombay High Court in the Bayer case, that to manufacture in India is not a necessary pre condition in all cases to establish patent's working in India. However, the onus is on the patent holder to establish the reasons which make it impossible to manufacture the patented drug in India, particularly when the Patentee has manufacturing facilities within the country. Hence the Controller stated that in the present application since the Applicant has failed to show the exact requirement of SAXAGLIPTIN in terms of the number of patients requiring it or whether it is in shortage, it is very difficult to conclude whether manufacturing in India is necessary or not.


In the above case, the Applicant has failed to provide evidence along with application or during hearing or supplementary submission. Further, the Applicant had failed to convince the Controller regarding any of the grounds specified under Section 84(1) of the Patents Act, therefore the Controller rejected the application for Compulsory License with a view that a prima facie case has not been made out under Section 84 of the Indian Patents Act.


1 Application_20January2016.pdf

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions